BR112023020483A2 - Compostos para inibir nlrp3 e usos dos mesmos - Google Patents

Compostos para inibir nlrp3 e usos dos mesmos

Info

Publication number
BR112023020483A2
BR112023020483A2 BR112023020483A BR112023020483A BR112023020483A2 BR 112023020483 A2 BR112023020483 A2 BR 112023020483A2 BR 112023020483 A BR112023020483 A BR 112023020483A BR 112023020483 A BR112023020483 A BR 112023020483A BR 112023020483 A2 BR112023020483 A2 BR 112023020483A2
Authority
BR
Brazil
Prior art keywords
compounds
nlrp3
inhibit nlrp3
inhibit
inhibited
Prior art date
Application number
BR112023020483A
Other languages
English (en)
Inventor
Alexandre Côté
Amandine Chefson
Jason Burch
Miguel St-Onge
Ramsay Beveridge
Stéphane Ciblat
Stéphane Dorich
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of BR112023020483A2 publication Critical patent/BR112023020483A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

compostos para inibir nlrp3 e usos dos mesmos. a presente divulgação refere-se a inibidores de nlrp3 úteis no tratamento de doenças e distúrbios inibidos pela referida proteína e com a fórmula (i).
BR112023020483A 2021-04-07 2022-04-07 Compostos para inibir nlrp3 e usos dos mesmos BR112023020483A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof
PCT/US2022/023893 WO2022216971A1 (en) 2021-04-07 2022-04-07 Pyridazine compounds for inhibiting nlrp3

Publications (1)

Publication Number Publication Date
BR112023020483A2 true BR112023020483A2 (pt) 2023-11-21

Family

ID=81385286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020483A BR112023020483A2 (pt) 2021-04-07 2022-04-07 Compostos para inibir nlrp3 e usos dos mesmos

Country Status (14)

Country Link
US (5) US11319319B1 (pt)
EP (2) EP4331668A3 (pt)
JP (2) JP2024514837A (pt)
KR (1) KR20230167394A (pt)
CN (2) CN117510495A (pt)
AU (2) AU2022256052A1 (pt)
BR (1) BR112023020483A2 (pt)
CA (1) CA3214676A1 (pt)
CL (1) CL2023002973A1 (pt)
CO (1) CO2023013356A2 (pt)
IL (2) IL308378A (pt)
PE (1) PE20240765A1 (pt)
TW (2) TW202304905A (pt)
WO (1) WO2022216971A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN115433163A (zh) * 2021-06-05 2022-12-06 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
AR126351A1 (es) 2021-07-02 2023-10-11 Astrazeneca Ab Compuestos y sus sales inhibidores del inflamasoma nlrp3
IL310264A (en) 2021-07-21 2024-03-01 Nico Therapeutics Inc A ring pyridine compound
WO2023028534A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. Inhibitors of nlrp3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
CN116102535A (zh) * 2021-10-22 2023-05-12 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2023183943A1 (en) * 2022-03-25 2023-09-28 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
WO2023186020A1 (en) * 2022-03-31 2023-10-05 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
US20240034735A1 (en) * 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
WO2024064245A1 (en) 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) * 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
WO2024097629A1 (en) * 2022-10-31 2024-05-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
CN117986258A (zh) * 2022-11-04 2024-05-07 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303061A (pt) * 1969-05-03 1973-01-17
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
ATE267174T1 (de) * 1994-08-09 2004-06-15 Eisai Co Ltd Kondensierte pyridazinverbindungen
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
AU2005260102A1 (en) * 2004-05-08 2006-01-12 Novartis International Pharmaceutical Ltd. 3-aryl-5,6-disubstituted pyridazines
WO2018080216A1 (en) * 2016-10-28 2018-05-03 Daewoong Pharmaceutical Co., Ltd. Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof

Also Published As

Publication number Publication date
US20220340567A1 (en) 2022-10-27
IL308378A (en) 2024-01-01
CL2023002973A1 (es) 2024-03-08
EP4331668A3 (en) 2024-06-05
AU2022256052A1 (en) 2023-11-16
IL307303A (en) 2023-11-01
EP4320102A1 (en) 2024-02-14
WO2022216971A1 (en) 2022-10-13
WO2022216971A9 (en) 2022-12-08
PE20240765A1 (es) 2024-04-17
TW202330522A (zh) 2023-08-01
CN117500792A (zh) 2024-02-02
JP2024514837A (ja) 2024-04-03
US20230159526A1 (en) 2023-05-25
US20240158396A1 (en) 2024-05-16
CO2023013356A2 (es) 2023-10-30
US11319319B1 (en) 2022-05-03
CA3214676A1 (en) 2022-10-13
AU2023263450A1 (en) 2023-11-23
EP4331668A2 (en) 2024-03-06
US20240174668A1 (en) 2024-05-30
TW202304905A (zh) 2023-02-01
CN117510495A (zh) 2024-02-06
JP2024050527A (ja) 2024-04-10
KR20230167394A (ko) 2023-12-08

Similar Documents

Publication Publication Date Title
BR112023020483A2 (pt) Compostos para inibir nlrp3 e usos dos mesmos
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112021026395A2 (pt) Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8
BR112019007143A2 (pt) compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
BR112016007751A2 (pt) composições para modulação de expressão de c9orf72
EA200700220A1 (ru) Имидазотриазины в качестве ингибиторов протеинкиназы
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112015024678A2 (pt) inibidor da cinase
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
EA201490537A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022015110A2 (pt) Compostos e usos dos mesmos
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
BRPI0509653A (pt) inibidores cinesina mitótica
CL2020002317A1 (es) Compuesto inhibidor de tirosina quinasa c-abl: modalidades y métodos de fabricación y uso
BR112022014949A2 (pt) Compostos e usos dos mesmos